Posted by Michael Wonder on 19 Nov 2019
Game changing cancer medicines now within reach for 2,200 Australians
20 November 2019 - Australians living with non-small cell lung cancer and early stage acute lymphoblastic leukaemia will be able to access better treatment options with new listings on the Pharmaceutical Benefits Scheme (PBS) coming into effect on 1 December 2019.
More than 2,200 patients with metastatic non-small cell lung cancer will now be able to access Keytruda (pembrolizumab) as a first line treatment in combination with chemotherapy.
This means most patients will not have to fail treatment with chemotherapy before accessing this game changing treatment for this condition.
